Pages that link to "Q26799266"
Jump to navigation
Jump to search
The following pages link to Fc glycans of therapeutic antibodies as critical quality attributes (Q26799266):
Displaying 50 items.
- Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications (Q26738810) (← links)
- Engineering antibody therapeutics (Q26741445) (← links)
- Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer (Q26748089) (← links)
- Posttranslational Modifications and the Immunogenicity of Biotherapeutics (Q26748614) (← links)
- Fc gamma receptors: glycobiology and therapeutic prospects (Q28076303) (← links)
- Glycan analysis of therapeutic glycoproteins (Q28082842) (← links)
- Data Independent Analysis of IgG Glycoforms in Samples of Unfractionated Human Plasma. (Q31131930) (← links)
- Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes (Q33891585) (← links)
- Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies (Q35990992) (← links)
- Human plasma protein N-glycosylation (Q36963945) (← links)
- Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus (Q37159302) (← links)
- Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells (Q37589825) (← links)
- Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab. (Q37703405) (← links)
- Statistical characterization of therapeutic protein modifications (Q38628116) (← links)
- Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF. (Q38696361) (← links)
- Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. (Q38699354) (← links)
- Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy. (Q38762019) (← links)
- Biological roles of glycans (Q38936714) (← links)
- Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology (Q38957458) (← links)
- Quantitative glycomics using liquid phase separations coupled to mass spectrometry. (Q39124498) (← links)
- Characterization of isomeric glycan structures by LC-MS/MS. (Q39215799) (← links)
- Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants (Q40011916) (← links)
- Automated N-Glycosylation Sequencing Of Biopharmaceuticals By Capillary Electrophoresis (Q41718512) (← links)
- Reduced paucimannosidic N-glycan formation by suppression of a specific β-hexosaminidase from Nicotiana benthamiana (Q42105653) (← links)
- Pharmacokinetics of Monoclonal Antibodies. (Q42118646) (← links)
- A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins. (Q42280824) (← links)
- Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development (Q44852748) (← links)
- Designing a mutant Candida uricase with improved polymerization state and enzymatic activity (Q46257023) (← links)
- Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties. (Q47265866) (← links)
- Structural characterization of the Man5 glycoform of human IgG3 Fc. (Q47445247) (← links)
- Beyond binding: antibody effector functions in infectious diseases. (Q47602559) (← links)
- N-Glycosylation of an IgG antibody secreted by Nicotiana tabacum BY-2 cells can be modulated through co-expression of human β-1,4-galactosyltransferase (Q48089742) (← links)
- Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies. (Q48134110) (← links)
- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review (Q49979586) (← links)
- Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability (Q50048248) (← links)
- Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study (Q50098437) (← links)
- The process defines the product: what really matters in biosimilar design and production? (Q50115805) (← links)
- A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies (Q50199955) (← links)
- Genome-Wide Association Study on Immunoglobulin G Glycosylation Patterns (Q51763368) (← links)
- An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. (Q52373100) (← links)
- Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. (Q52648922) (← links)
- Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. (Q52684751) (← links)
- Structure of the Lassa virus glycan shield provides a model for immunological resistance (Q56941600) (← links)
- Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap (Q56999931) (← links)
- Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry (Q57165000) (← links)
- Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective (Q57460672) (← links)
- Measurement of impurities to support process development and manufacture of biopharmaceuticals (Q58338044) (← links)
- Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody (Q58546594) (← links)
- A single amino acid distorts the Fc γ receptor IIIb / CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a (Q58558231) (← links)
- Improving Immunotherapy Through Glycodesign (Q59132146) (← links)